These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1307777)

  • 1. Therapeutic effect of gevilon in patients with hyperlipoproteinaemia.
    Milewicz A; Plamieniak Z; Bohdanowicz-Pawlak A
    Mater Med Pol; 1992; 24(2):91-5. PubMed ID: 1307777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gemfibrozil in the treatment of hyperlipoproteinemia].
    Ceska R; Sobra J
    Vnitr Lek; 1989 Oct; 35(10):967-71. PubMed ID: 2617883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
    Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of fenofibrate in various types of hyperlipoproteinemias].
    Sucić M
    Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-HDL cholesterol and apoB in dyslipidaemia.
    Sniderman AD; Hogue JC; Bergeron J; Gagné C; Couture P
    Clin Sci (Lond); 2008 Jan; 114(2):149-55. PubMed ID: 17868037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
    Paragh G; Balogh Z; Boda J; Mohácsi A; Juhász A; Leövey A
    Orv Hetil; 1993 Jan; 134(3):121-4. PubMed ID: 8421622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Duolip Forte--experience during a 6-month period of administration].
    Toschnerová H; Ceska R; Sobra J; Traurig J
    Cas Lek Cesk; 1993 May; 132(10):308-10. PubMed ID: 8513467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Gevilon therapy and its relation to E polymorphism].
    Németh A; Dinya E; Audikovszky M; Pados G; Mannfred H
    Orv Hetil; 1994 Apr; 135(14):735-41. PubMed ID: 8170672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
    Paragh G; Balogh Z; Boda J; Kovács P; Kárpáti L; Szabó J; Leövey A
    Acta Biol Hung; 1997; 48(3):359-67. PubMed ID: 9406614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
    Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia.
    Stefanutti C; Vivenzio A; Lucani G; Di Giacomo S; Lucani E
    Clin Ter; 1998; 149(2):115-9. PubMed ID: 9780475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
    Ceska R; Sobra J; Procházková R; Kvasilová M
    Vnitr Lek; 1990 Apr; 36(4):363-7. PubMed ID: 2356612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipid-reducing basic diet and serum fatty acid levels].
    Reuter W
    Z Gesamte Inn Med; 1980 Sep; 35(18):701-6. PubMed ID: 7445612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
    Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
    Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.